122 related articles for article (PubMed ID: 30171788)
21. Adjuvant effect of Japanese herbal medicines on the mucosal type 1 immune responses to human papillomavirus (HPV) E7 in mice immunized orally with Lactobacillus-based therapeutic HPV vaccine in a synergistic manner.
Taguchi A; Kawana K; Yokoyama T; Adachi K; Yamashita A; Tomio K; Kojima S; Oda K; Fujii T; Kozuma S
Vaccine; 2012 Aug; 30(36):5368-72. PubMed ID: 22727726
[TBL] [Abstract][Full Text] [Related]
22. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
Li YL; Qiu XH; Shen C; Liu JN; Zhang J
Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
[TBL] [Abstract][Full Text] [Related]
23. In Silico Design and Immunological Studies of Two Novel Multiepitope DNA-Based Vaccine Candidates Against High-Risk Human Papillomaviruses.
Kayyal M; Bolhassani A; Noormohammadi Z; Sadeghizadeh M
Mol Biotechnol; 2021 Dec; 63(12):1192-1222. PubMed ID: 34308516
[TBL] [Abstract][Full Text] [Related]
24. A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice.
Granadillo M; Vallespi MG; Batte A; Mendoza O; Soria Y; Lugo VM; Torrens I
Vaccine; 2011 Jan; 29(5):920-30. PubMed ID: 21145912
[TBL] [Abstract][Full Text] [Related]
25. NSP4 as adjuvant for immunogenicity and design of effective therapeutic HPV16 E6/E7/L1 DNA vaccine in tumor-bearing and healthy C57BL/6 mice.
Sadr-Momtaz S; Aftabi M; Behboudi E; Naderi M; Hashemzadeh-Omran A; Moradi A
BMC Res Notes; 2023 Aug; 16(1):164. PubMed ID: 37550734
[TBL] [Abstract][Full Text] [Related]
26. Non-replicating Newcastle Disease Virus as an adjuvant for DNA vaccine enhances antitumor efficacy through the induction of TRAIL and granzyme B expression.
Mohebbi A; Ebrahimzadeh MS; Baghban Rahimi S; Saeidi M; Tabarraei A; Mohebbi SR; Shirian S; Gorji A; Ghaemi A
Virus Res; 2019 Feb; 261():72-80. PubMed ID: 30599161
[TBL] [Abstract][Full Text] [Related]
27. A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection.
Demurtas OC; Massa S; Ferrante P; Venuti A; Franconi R; Giuliano G
PLoS One; 2013; 8(4):e61473. PubMed ID: 23626690
[TBL] [Abstract][Full Text] [Related]
28. HSP70 modified response against HPV based tumor.
Farzanehpour M; Soleimanjahi H; Hassan ZM; Amanzadeh A; Ghaemi A; Fazeli M
Eur Rev Med Pharmacol Sci; 2013 Jan; 17(2):228-34. PubMed ID: 23377813
[TBL] [Abstract][Full Text] [Related]
29. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
Yang Y; Che Y; Zhao Y; Wang X
Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
[TBL] [Abstract][Full Text] [Related]
30. MPG-based nanoparticle: An efficient delivery system for enhancing the potency of DNA vaccine expressing HPV16E7.
Saleh T; Bolhassani A; Shojaosadati SA; Aghasadeghi MR
Vaccine; 2015 Jun; 33(28):3164-70. PubMed ID: 26001433
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxic T lymphocytes elicited by dendritic cell-targeted delivery of human papillomavirus type-16 E6/E7 fusion gene exert lethal effects on CaSki cells.
Wu XM; Liu X; Jiao QF; Fu SY; Bu YQ; Song FZ; Yi FP
Asian Pac J Cancer Prev; 2014; 15(6):2447-51. PubMed ID: 24761845
[TBL] [Abstract][Full Text] [Related]
32. Increased Response of Human T-Lymphocytes by Dendritic Cells Pulsed with HPV16E7 and Pleurotus sajor-caju-β-glucan (PBG).
Roopngam PE
Iran J Immunol; 2018 Dec; 15(4):246-255. PubMed ID: 30593739
[TBL] [Abstract][Full Text] [Related]
33. Small heat shock protein 27: An effective adjuvant for enhancement of HIV-1 Nef antigen-specific immunity.
Milani A; Bolhassani A; Shahbazi S; Motevalli F; Sadat SM; Soleymani S
Immunol Lett; 2017 Nov; 191():16-22. PubMed ID: 28917624
[TBL] [Abstract][Full Text] [Related]
34. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
Wick DA; Webb JR
Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
[TBL] [Abstract][Full Text] [Related]
35. DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice.
Bahrami AA; Ghaemi A; Tabarraei A; Sajadian A; Gorji A; Soleimanjahi H
J Virol Methods; 2014 Sep; 206():12-8. PubMed ID: 24880067
[TBL] [Abstract][Full Text] [Related]
36. Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model.
Salehi M; Taheri T; Mohit E; Zahedifard F; Seyed N; Taslimi Y; Sattari M; Bolhassani A; Rafati S
Immunotherapy; 2012 Nov; 4(11):1107-20. PubMed ID: 23194361
[TBL] [Abstract][Full Text] [Related]
37. Simultaneous use of natural adjuvants and cell penetrating peptides improves HCV NS3 antigen-specific immune responses.
Alizadeh S; Irani S; Bolhassani A; Sadat SM
Immunol Lett; 2019 Aug; 212():70-80. PubMed ID: 31254535
[TBL] [Abstract][Full Text] [Related]
38. Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses.
Oosterhuis K; Aleyd E; Vrijland K; Schumacher TN; Haanen JB
Hum Gene Ther; 2012 Dec; 23(12):1301-12. PubMed ID: 22971245
[TBL] [Abstract][Full Text] [Related]
39. Long-lasting immunoprotective and therapeutic effects of a hyperstable E7 oligomer based vaccine in a murine human papillomavirus tumor model.
Cerutti ML; Alonso LG; Tatti S; de Prat-Gay G
Int J Cancer; 2012 Apr; 130(8):1813-20. PubMed ID: 21780110
[TBL] [Abstract][Full Text] [Related]
40. Development of HCV Therapeutic Vaccines Using Hp91 Peptide and Small Heat Shock Protein 20 as an Adjuvant.
Basirnejad M; Bolhassani A
Protein Pept Lett; 2018; 25(10):924-932. PubMed ID: 30255740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
